Health Care Equipment

HeartBeam

LEAPMOTOR

Financial Analysis

09863

01211

BYDDF

81211

BYDDY

002594

BEAT

PATH

BEATW

HYDD

The significant increase in the three expenses has eroded Leapmotor's net profit.

Sensata Tech

North American Energy Par

BYD COMPANY

BYD Company Limited

BYD COMPANY-R

BYD Company

UiPath

Outbrain

HEARTBEAM INC C/WTS 31/10/2026 (TO PUR COM)

BYD HK SDR 10to1

Leapmotor: The 'leading' momentum encounters obstacles, how to break through the blood path?

Palantir

PLTR

TECH

BACK

$Palantir Tech(PLTR.US) released its Q3 2025 earnings after the market closed on November 3rd, Eastern Time. Overall, the Q2 performance remains impressive. Although the guidance and operational indicators imply signs of slowing down, considering the management's consistently conservative guidance style and the short-term changes in the U.S. Department of Defense procurement process, the short-term disturbances are not a major issue. However, with a full valuation, the market will be more critical of Palantir. Reviewing past performance versus market reactions, it is not difficult to find that from the three quarters starting this year, as the valuation rises...

Palantir Tech

Bio-Techne

Mirae Asset Global Investments Co., Ltd.

First Commonwealth Financial PA

Imac

Palantir: Expensive Valuation is Biting Back!

Meta/Facebook

NVDA

NVDL

07788

07388

NVDY

NVDD

NVDX

NVDQ

Hello everyone, I am Dolphin Research! $Meta Platforms(META.US) released its Q3 2025 financial report after the market closed on October 30th, Eastern Time. Although the 'horrifying' net profit of 2.7 billion is 'noise', this performance, especially the underlying trends implied by the revenue and expenditure guidance combination, is definitely not something to celebrate. Specifically: 1. Strong acceleration in advertising: Advertising revenue grew by 26%, further accelerating growth. According to advertiser research..

Meta Platforms

NVIDIA

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

Direxion Daily NVDA Bear 1X ETF

T-Rex 2X Long NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

Meta: AI investment in 'reckless driving', is the faith in capital going to be exhausted?

Google

GOOG

GOOGL

OpenAI

DXYZ

GGLS

GGLL

ASIC

PLAY

GEMI

After the market closed on October 29th, Eastern Time, $Alphabet(GOOGL.US) $Alphabet - C(GOOG.US) parent company Alphabet released its Q3 2025 financial report. After two months of revaluation under the logic of full-stack AI, with limited room for direct recovery and the market urgently needing further reasons to rise, Google delivered an impressive performance to continue its revaluation path. Specifically, the core information is as follows: 1. Explosive advertising performance: In the third quarter, YouTube and search ads both grew by 15%, exceeding market expectations...

Alphabet - C

Alphabet

Destiny Tech100

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Grupo Televisa

Ategrity Specialty Holdings LLC

Dave & Buster ENT

Gemini Space Station

Google's Dramatic Turnaround: From AI 'Sacrifice' to AI 'Trendsetter'

Conference Minutes

AVGO

NOA3

ORCL

AMDL

BLUE

OPEN

IONQ

OPENL

OPENW

OPENZ

1. Key Points of the GTC Conference 1. NVIDIA has established a strategic partnership with Nokia, investing $1 billion in Nokia's equity. They released a new product series called 'NVIDIA ARC,' which Nokia will use for future base stations to upgrade 6G and AI capabilities; 2. They released the NVQLink interconnect architecture and the CUDAQ platform, which directly connects GPU supercomputers with QPUs (quantum processors), laying the groundwork for quantum computing processors; 3. $NVIDIA(NVDA.US) is collaborating with the U.S. Department of Energy to build the largest AI supercomputer in the United States...

Broadcom

Nokia Oyj

Oracle

GraniteShares 2x Long AMD Daily ETF

Bluebird Bio

Opendoor Tech

IonQ

Opendoor Tech Series A - CW26

Opendoor Tech Series K - CW26

Opendoor Tech Series Z - CW26

 GTC Conference: Next Year's Shipment 'Blockbuster', is NVIDIA‘s Limit Really “Sky”？

HeartBeam released FY2026 Q1 earnings on May 13 After-Market EST, actual revenue USD 0 (forecast USD 149.75 K), actual EPS USD -0.1199 (forecast USD -0.135)

HeartBeam to release FY2026 Q1 earnings on May 13 After-Market EST, forecast revenue USD 119.8K, EPS USD -0.138

HeartBeam released FY2025 Q4 earnings on March 12 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.147 (forecast USD -0.1375)

HeartBeam released FY2025 earnings on March 12 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6234 (forecast USD -0.6125)

HeartBeam to Release FY2025 Q4 Earnings on March 12 After-Market EST, Forecast EPS -0.1375 USD

HeartBeam to Attend JPMorgan Healthcare Conference to Discuss Upcoming Commercial Release and FDA Approval

HeartBeam Inc. Shareholder Mark E. Strome Sells Common Stock

HeartBeam released FY2025 Q3 earnings on November 13 After-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1527 (forecast USD -0.155)

HeartBeam released FY2025 9 Months Earnings on November 13 After-Market EST with actual revenue of USD 0 and EPS of USD -0.4803

HeartBeam Inc. Reports Financial Data and Advances ECG Software Approval

HeartBeam to Release FY2025 Q3 Earnings on November 13 After-Market EST, Forecast EPS USD -0.155

Analyst Bauser Covers Healthcare Sector Focusing on Specific Stocks

HeartBeam released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 0, actual EPS USD -0.3249

HeartBeam released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.147 (forecast USD -0.18)

HeartBeam to Release FY2025 Q2 Earnings on August 13 After-Market EST, Forecast EPS USD -0.18

HeartBeam Annual Shareholders Meeting Held

HeartBeam's Stock Dips as Insiders Buy

HeartBeam released FY2025 Q1 earnings on May 13 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1805 (forecast USD -0.16)

HeartBeam reports Q1 loss of $0.18 per share

HeartBeam Reports High Precision ECG Study Results

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

HeartBeam (NASDAQ:BEAT) reported its Q1 2026 financial results, highlighting successful commercialization efforts, including partnerships with ClearCardio and Atelier Health. The company is advancing its 12-lead patch development and AI collaborations, with clinical studies for heart attack detection ahead of schedule. HeartBeam secured $11.5 million in financing, ensuring a cash runway into 2027. Management aims for a break-even point with 30,000 patients and is exploring further partnerships for expansion. The earnings call included discussions on growth initiatives and the company's unique technology platform.

benzinga_article

HeartBeam Q1 2026 Earnings Call: Complete Transcript

HeartBeam, Inc. (NASDAQ: BEAT) has initiated a pilot study for its innovative on-demand 12-lead ECG patch aimed at detecting ischemia in patients with suspected coronary artery disease. Conducted in Serbia, the study will enroll around 50 patients and compare the patch's synthesized ECG with standard 12-lead ECGs. This device, leveraging patented 3D ECG technology, aims to expand cardiac monitoring capabilities beyond rhythm assessment, targeting a $2 billion market with established reimbursement pathways. HeartBeam's CEO emphasized the potential of this technology to transform cardiac care outside traditional settings.

StockTitan

iShares US Medical Devices

SPDR S&P Health Equip

HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic | BEAT Stock News

HeartBeam, Inc. (NASDAQ: BEAT) will host a conference call on May 13, 2026, at 4:30 p.m. ET to discuss its Q1 2026 results and updates on strategic growth initiatives, including its arrhythmia assessment launch and AI developments. The call will feature CEO Robert Eno and CFO Timothy Cruickshank, followed by a Q&A session. A press release with results will be issued prior to the call. Access details for the call and a replay will be provided.

HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time | BEAT Stock News

IMMP

NOTV

In Wednesday's trading session, several health care stocks experienced significant movements. Immutep (NASDAQ:IMMP) surged 92.2% to $0.6, while Cue Biopharma (NASDAQ:CUE) rose 40.2% to $0.61. Other gainers included PDS Biotechnology (NASDAQ:PDSB) up 22.64% to $1.3, and Inotiv (NASDAQ:NOTV) up 21.87% to $0.3. Conversely, Aspire Biopharma Holdings (NASDAQ:ASBP) saw a sharp decline of 46.6% to $0.64, followed by HeartBeam (NASDAQ:BEAT) down 32.08% to $0.82. Overall, the session highlighted notable volatility in the health care sector.

Immutep

Inotiv

Cue BioPharma

PDS Biotechnology

iShares Genomics Immunology and Healthcare ETF

ALPS Medical Breakthrough

VG Health

iShares US Healthcare Providers

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares Global Healthcare

VanEck Biotech ETF

iShares Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Cosmos Health

Propanc Biopharma

Aspire Biopharma

Clearmind Medicine

Traws Pharma

Onconetix

Lunai Bioworks

Immutep Ltd

PROPANC BIOPHARMA INC

ASPIRE BIOPHARMA HOLDINGS INC C/WTS 14/02/2030 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Intraday Session

Heartbeam shares are trading lower after the company announced the pricing of its $10 million public offering of 12.5 million shares.

HeartBeam(BEAT.US)

HeartBeam Q1 2026 Earnings Call: Complete Transcript

HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic | BEAT Stock News

HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time | BEAT Stock News

12 Health Care Stocks Moving In Wednesday's Intraday Session

Heartbeam shares are trading lower after the company announced the pricing of its $10 million public offering of 12.5 million shares.